Revenue for 2017 soared to
Lojuxta is used to treat a life-threatening disease called homozygous familial hypercholesterolaemia.
Further sales growth will come, Amryt said, in 2018 from both existing and new markets, and the company has signed five new distributor deals since November.
The company has signed an exclusive in-licence of a new platform technology for gene therapy from University College Dublin. Amryt will conduct various pre-clinical studies in the coming months with results due in the last quarter of 2018.
Amryt also said it is amending the protocol for its phase III study of AP101, increasing the study size and restricting certain wound types. This will delay slightly interim analysis which it expects to be completed early in 2018's fourth quarter, with a read-out due in the second quarter of 2019.
The cost of these changes is expected to be approximately
Chief Executive Joe Wiley said: "2017 was a very strong year for Amryt and we are encouraged by the start to 2018, which places us in a good position to be able to drive further expansion through this year and beyond.
"We have grown our Lojuxta business significantly since we in-licensed it in December 2016, and our recent distribution agreements throughout
He added: "We have ambitious plans for the remainder of 2018 and we look forward to announcing a series of agreements in the months to come. This is a pivotal year for Amryt and our focus continues to be on ensuring that we are delivering real change for people with rare diseases across the world. I am proud to say we are delivering on our promise."
Shares were down 0.1% on Thursday at
